In January 2008, Ligand Pharmaceuticals, through its marketing partner, Pfizer, submitted a New Drug Application for lasofoxifene, which is expected to be marketed under the tradename Fablyn.
In January 2008, Ligand Pharmaceuticals, via its marketing accomplice, Pfizer, submitted a New Drug Application for lasofoxifene, which is anticipated to be sold under the brand name Fablyn.